Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


ACE evaluated the cardiovascular effects of adding daily treatment with acarbose to usual care in patients with coronary heart disease and impaired glucose tolerance (IGT).


Randomised, placebo controlled clinical trial co-ordinated by the Diabetes Trials Unit. Between 2009 and 2015, 6522 patients from 176 hospitals in mainland China and Hong Kong were randomly assigned and included in the intention-to-treat population.


The results of ACE were reported at the 2017 meeting of the EASD. They showed that in Chinese patients with coronary heart disease and impaired glucose tolerance, acarbose did not reduce the risk of major adverse cardiovascular events, but did reduce the incidence of diabetes by 18%. The primary results paper is available here.

Manuscript proposals

The ACE Publications Committee are happy to review proposals for potential new manuscripts. Proposals should be submitted on an ACE Ancillary Study Request Form emailed to

Chair Rury Holman
Co-chairs Hu Dayi
Pan Changyu
Sponsor University of Oxford
Funder Bayer AG
Reference number ISRCTN91899513